VIRAL VECTOR AND PLASMID DNA TESTING SERVICES MARKET ANALYSIS

Market Challenges And Opportunities

Global Viral Vector and Plasmid DNA Testing Services Market– Drivers

Increasing number of inorganic growth strategies such as partnership and others

Increasing adoption of inorganic growth strategies such as collaboration, partnership and others by the key market players is expected to fuel the segmental growth of the over the forecast period. For instance, in October 2022, Charles River Laboratories International, Inc., a pharmaceutical company and Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced a comprehensive manufacturing collaboration utilizing Charles River's extensive contract development and manufacturing (CDMO) services in both plasmid DNA and viral vectors.

Global Viral Vector and Plasmid DNA Testing Services Market: Restraints

Requirement of highly Skilled Labor

Production of recombinant plasmid DNA requires advanced manufacturing equipment and facilities and highly experienced and skilled labor. Limited number of Contract Development and Manufacturing Organizations (CDMOs) and biopharmaceutical companies have enough resources at all stages of the product development cycle. Majority of CDMOs providing commercial and clinical manufacturing and development services and academic laboratories providing early phase support, are running at high capacity, typically with longer wait list.

Challenges Faced During DNA Supply

Biotech and pharmaceutical companies that are majorly focused on advanced therapy manufacturing face challenges associated with their plasmid DNA supply, which includes slow or delayed production and poor DNA quality, and impacting their ability to meet timelines and regulatory demands. However, the regenerative medicine industry is also experiencing challenges and limitations with genetic medicines. Almost, every genetic medicines today are dependent on plasmid DNA as either critical starting material or API (Application Programming Interface), which presents challenges in advanced therapy manufacturing.

Global Viral Vector and Plasmid DNA Testing Services Market- Key Trends

Increasing number of investment by market players for product development

Increasing number of investment by the market players in for product development is expected to foster the market growth over the forecast period. For instance, in September, 2022, Trans-Atlantic private equity healthcare specialist, ArchiMed, invested in Bielefeld, Germany-based PlasmidFactory. PlasmidFactory is the contract manufacturer and service provider for plasmid and minicircle DNA. PlasmidFactory develops and manufactures exceptionally high-grade plasmids and minicircle, used to modify cells and produce viral gene therapy vectors such as Adeno-associated virus (AAV), Lentiviral vectors (LV) and mRNA for combating everything from viruses such as COVID-19 to seemingly intractable diseases such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDs (including CAR-T cell applications). Plasmids are notably a key component for the production of mRNA COVID-19 vaccines.

Partnership by key market players

Key players are focused on partnerships to strengthen their position, is expected to fuel the global viral vector and plasmid DNA testing services market over the forecast period. For instance, on October 17, 2022, GenScript ProBio, a global CDMO, and GeneCraft, a global research of lung cancer mechanism research, announced that they had entered into a strategic partnership MOU concerning the development and production of a new drugs needed for RX001. GenScript ProBio and GeneCraft have agreed to strengthen their cooperation in the AAV gene therapy field through this MoU. GenScript ProBio and GeneCraft are in the process of signing a contract for plasmid and AAV development and production for the GeneCraft's own new drug candidate Pan-KRAS non-small cell lung cancer anti-cancer gene therapy (RX001) developed as a new drug.